Official communication about our medicines containing semaglutide from Novo Nordisk This site is intended for a US audience Latest on compounded and counterfeit products and other important information about semaglutide Latest on compounded and counterfeit products and other semaglutide information Patient safety is our top priority, and we are concerned about unapproved compounded semaglutide exposing patients to serious safety and efficacy risks
From physiology to pharmacology Our discovery of GLP-1 as a satiety hormone was patented in collaboration with the pharmaceutical company Novo Nordisk A/S in November 1996 [7] (I receive no royalty or other payments)
do not freeze reconstituted solution
Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice
Through rigorous scientific testing, these trials provide valuable insights into the potential benefits and risks associated with this innovative treatment option
The best option depends on your health goals, medical history, and what your provider recommends